Markets

Concert Pharmaceuticals (CNCE) Jumps: Stock Rises 23.1%

Concert Pharmaceuticals, Inc. ( CNCE ) was a big mover last session, as its shares rose over 23% on the day. The upside was driven by encouraging phase 1 results for the company's experimental drug CTP-656. This also led to far more shares changing hands than in a normal session. Yesterday's rally continues the recent uptrend for the company, as the stock is now up over 51% in the past one-month time frame.

Over the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Concert Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked med-drugs stock is Alcobra Ltd. ( ADHD ) with a Zacks Rank #1 (Strong Buy).

Is CNCE going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CONCERT PHARMA (CNCE): Free Stock Analysis Report

ALCOBRA LTD (ADHD): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CNCE

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More